RecruitingNCT06794307

Blood Glucose in Pregnant Non-diabetic Women During Treatment With Betamethasone for Fetal Lung Maturation

Blood Glucose Levels in Pregnant Non-diabetic Women During Treatment With Betamethasone for Fetal Lung Maturation


Sponsor

University of Aarhus

Enrollment

25 participants

Start Date

Nov 20, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

In case of threatening preterm birth, it is standard to recommend treatment with betamethasone to accelerate fetal lung maturation. In pregnant women with diabetes, treatment with betamethasone can lead to significant hyperglycemia, which may cause hypoglycemia in the neonate. Changes in blood glucose in non-diabetic women are less investigated. In this study we aim to examine changes in maternal blood glucose levels in non-diabetic women, during treatment with betamethasone, by continuous glucose monitoring. Hypotheses: Administration of betamethasone induce significant hyperglycemia in non-diabetic pregnant women during treatment.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria6

  • Pregnant in gestational week 24+0 - 34+0 admitted with symptoms of threatened preterm birth:
  • Premature contractions and shortening of the cervix, or
  • Preterm premature rupture of membranes.
  • Treatment with betamethasone for fetal lung maturation is planned, or started (maximum 4 hours before inclusion)
  • Age over 18 years
  • Read and understand Danish

Exclusion Criteria3

  • Multiple pregnancy
  • Diabetes
  • Pre-existing maternal use of medications that affect glucose metabolism

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Aarhus University Hospital

Aarhus, Central Region Denmark, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06794307


Related Trials